If
you read a newspaper or watched television news on December 10, 2008, you would
have thought that Crestor, a cholesterol-lowering statin medication, was a wonder
drug.
Of
course, a few years ago you would have thought the same thing after the heavy
news coverage for another powerful statin, Lipitor. Yet, my analyses at MedicationSense
(2005, 2006) revealed that the Lipitor studies demonstrated limited benefits and
worrisome adverse effects.
The
new Crestor study, which involved more than 17,000 subjects, examined the drug's
effectiveness in reducing elevated blood levels of C-reactive protein (CRP), a
marker for cardiovascular inflammation.1 It is currently believed that increased
levels of inflammation are associated with a higher incidence of heart attacks
and strokes (more on CRP below).
Crestor
Study Results -- and What They Really Mean
The authors of the Crestor-CRP study reported that over the 1.9 years of the study,
there was a 44% reduction in cardiac events (defined as heart attack, stroke,
severe angina, or cardiac death) among the subjects taking Crestor versus those
taking a placebo. A 44% reduction sounds very impressive, but it is misleading.
Here
on the actual numbers from the study. Over 2 years, 1.36% of subjects in the placebo
group experienced a cardiac event; 0.77% of subjects in the Crestor group experienced
an event. The difference was 0.59%. That is, less than 1%, a tiny difference.
The
difference was so tiny that it will require 120 individuals with elevated CRP
to take Crestor every day for two years for just one person to obtain benefit.2
Meanwhile, the other 119 individuals taking and paying for Crestor for two years
will obtain no protection from a cardiovascular event.
Why
would the results of the Crestor-CRP study be proclaimed so loudly nationwide
despite being so tiny? The Crestor-CRP study was underwritten by AstraZeneca,
the manufacturer of Crestor. We have seen previously that the marketing departments
of drug companies are masters at obtaining maximum media coverage for their studies
even if the results are unimpressive. Wide exposure means increased sales and
big profits.
One
media outlet took a critical stance. ABCNEWS.com boldly offered a dissenting opinion.
In "Doctor Urges Caution in Interpreting New Findings on Cholesterol Drug,"
Dr. Nortin Hadler wrote, "The benefit shown in this study is tiny, and if
[the Crestor-CRP study] were repeated, there might be no benefit at all. I never
leap to act on the basis of such small effects."3
Serious
Side Effects Downplayed
In Crestor-CRP, the drug displayed many of
the common adverse effects of other statin medications (Lipitor, Zocor, Pravachol,
Mevacor, Lescol). Typical side effects include abdominal pain, muscle pain, serious
muscle breakdown (rhabdomyolysis), renal disorders, and liver disorders. More
subjects in the Crestor group experienced these side effects than subjects in
the placebo group.
A
far more serious adverse effect occurred with Crestor: 270 cases of newly diagnosed
diabetes were reported among Crestor users, and 216 cases were reported among
placebo users. The 54 more cases of diabetes in the Crestor group was a significant
and worrisome finding. Diabetes is one of the most destructive, life-shortening
disorders of our time. It also is a leading cause of heart attacks and strokes.
Imagine, taking Crestor to prevent a heart attack and getting diabetes instead.
When
the FDA decides whether to approve a new drug, it makes it decision based on whether
the drug will produce significantly more benefit than risk. If Crestor were being
evaluated today for approval by the FDA, I believe Crestor would not be approved
because its use in the Crestor-CRP study was associated with many new cases of
diabetes.
Should
I Be Tested for Elevated CRP?
Half of all cardiac deaths occur in
people with normal cholesterol levels, so other factors cleary are involved in
the development of cardiovascular disease. New studies suggest that an elevated
level of CRP may be as important an indicator of cardiac risk as cholesterol levels.4.5
"Forward-thinking
cardiologists suspect that internal inflammation is the root cause of many diseases
including those of the heart and blood vessels," states cardiologist Stephen
Sinatra. "Studies have shown that people with elevated CRP run two times
the risk of dying from a cardiovascular-related problem compared with those who
have high cholesterol levels. Combine a cholesterol burden with a markedly elevated
CRP and your risk of heart attack and stroke increases by a factor of nine."6
Despite
this, experts still disagree on whether the entire population should be tested
for elevated CRP. I believe that anyone who has cardiovascular disease or is at
risk for it should be tested for elevated CRP. Furthermore, I also encourage anyone
interested in prevention to have a CRP test.
A
CRP level below 1 is low-risk; 1-3 moderate-risk; above 3 high-risk.
Should
My Elevated CRP Be Treated?
If your CRP level is elevated, it should
not be ignored. Yet this does not mean that your doctor should immediately prescribe
you a statin. As Dr. James Ehrlich, a pioneer in cardiovascular disease screening,
said, an elevated CRP "is a call for more information, not an invitation
to take an automation-like approach to prescribing life-long statins."7
An
elevated CRP indicates a higher than normal level of inflammation in the body.
Many medical conditions can produce inflammation. Your doctor should examine you
for signs of infection: teeth, sinuses, bladder, ovaries or prostate. A recent
cold or bout of the flu can also elevate CRP. Inflammatory disorders such as rheumatoid
arthritis may cause an elevated CRP.
If
no other causes of infection are found, the elevated CRP likely reflects cardiovascular
inflammation. Should it be treated? Experts differ on this, but in general I recommend
treatment.
Is
Crestor the Only Treatment for Elevated CRP?
No. There are many choices,
pharmaceutical and natural. This section will discuss statin therapy.
We
have known for a decade that the effects of all statins are similar. This means
that all statins can reduce elevated CRP.
In
the Crestor-CRP study, 20 mg of Crestor was used. This is a powerful dose, and
because Crestor is only available as a brand-need drug, it is expensive. At a
nationwide discount pharmacy, 100 pills of 20-mg Crestor costs $340. The cost
over one year is approximately $1360. Over 20 years, the cost of Crestor 20 mg
per day is approximately $27,000.8 An equally powerful dose, 80 mg, of Zocor is
available as a generic (simvastatin), and it costs about 90% less.
Just
because the Crestor-CRP study used a powerful dose of Crestor does not mean that
only a powerful dose will reduce elevated CRP. Some experts believe that it is
not necessary to use the same strong statin doses that doctors frequently prescribe
to reduce cholesterol levels. Elevated levels of CRP may not require such strong
treatment. According to Dr. Uve Ravnskov, "It may be wiser to search for
the lowest effective dose instead of the dose with maximal effect on LDL-cholesterol."9
If
you are prone to getting side effects with medications, or if you simply want
to reduce your risk of side effects, ask your doctor about starting with the lowest
dose of simvastatin. If this does not adequately reduce your elevated CRP level,
ask your doctor to increase the dose gradually until you arrive at the amount
that works. With Zocor (simvastatin), the lowest dose is 10 mg.
Natural
Approaches
Integrative doctors recommend a variety of natural approaches
to reduce elevated CRP. Because smoking increases CRP, the first step for any
smoker is to stop smoking. Being overweight increases CRP, so weight loss is also
important. Healthy eating and exercise can also reduce CRP levels.
Women
taking hormone replacement therapy should be aware that the therapy can increase
CRP levels.10 Check with your doctor.
There
are several natural supplements that have anti-inflammatory qualities. Alternative
doctors often include one, such as curcumin or ginger, in their combination treatment
for elevated CRP. Some alternative doctors include aspirin because of its proven
anti-inflammatory effect.
Vitamin
C might also be included in the treatment of elevated CRP. A study in the Journal
of the American College of Nutrition demonstrated that 515 mg/day of vitamin C
reduced CRP 24%.11 In comparison, in the Crestor-CRP study, Crestor reduced CRP
levels by an average up 37%. Vitamin C plus other therapies mentioned in this
section might rival or exceed this result.
Vitamin
E, with its natural anti-inflammatory effects, might also help reduce elevated
CRP.
Omega-3
fatty acids (fish oils) have proven anti-inflammatory effects. Studies have shown
that daily intake of omega-3 fatty acids reduce the risk of cardiac death and
also reduce the pain of rheumatoid arthritis.12,13 Fish oils should be a standard
part of the treatment of elevated CRP. Because fish oils and aspirin taken together
can increase the body's tendency for bleeding, check with your doctor before taking
these therapies together.
A
natural supplement with properties similar to prescription statins is red yeast
rice. This fermentation product contains small amounts of several statin-like
compounds. It works like a mild statin and, like prescription statins, reduces
vascular inflammation and elevated CRP. Red yeast rice can also reduce cholesterol
levels. Like prescription statins, red yeast rice can cause adverse effects, but
the risk is low and, if side effects occur, they are usually milder than with
prescription statins.
Copyright
2008, Jay S. Cohen, M.D. All rights reserved.
References
1.
Ridker PM, Danielson E, Fonseca FAH, et al (for the JUPITER Study Group). Rosuvastatin
to prevent vascular events in men and women with elevated C?reactive protein.
The New England Journal of Medicine, Nov. 20, 2008;359(21):2195?2207.
2.
Hlatky MA. Expanding the Orbit of Primary Prevention ?? Moving beyond JUPITER.
New England Journal of Medicine, Nov. 20, 2008;359 (21):2280?82.
3.
Hadler NM. Crestor, by Jove... or Not. Doctor urges caution in interpreting new
findings on cholesterol drug. ABC News, Nov. 10, 2008:http://abcnews.go.com.
4.
Ridker, PM, Rifai, N, Rose, L, et al. R. Comparison of C-reactive protein and
low-density lipoprotein cholesterol levels in the prediction of first cardiovascular
events. New England Journal of Medicine 2002;347:1557-1565.
5.
Albert, MA, Glynn, RJ, Ridker, PM. Plasma concentration of C-reactive protein
and the calculated. Framingham Coronary Heart Disease Risk Score. Circulation
2003;108(2):161?5.
6.
Sinatra, S. Statins: grossly overprescribed for cholesterol and underprescribed
for internal inflammation. The Sinatra Health Report, Sept. 2002;8:1.
7.
West A. JUPITER: separating the solid clinical matter from the hot gas. Holistic
Primary Care, Winter 2008;9(4):1-2.
9.
Ravnskov, U. Is atherosclerosis caused by high cholesterol? QJM (Quarterly Journal
of Medicine) 2002;95:397-403.
10.
Walsh, BW, Paul, S, Wild RA, et al. The Effects of Hormone Replacement Therapy
and Raloxifene on C?Reactive Protein and Homocysteine in Healthy Postmenopausal
Women: A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism
2004;85:214?218.
11.
Block, G, Jensen, C, Dietrich, M, et al. Plasma C-reactive protein concentrations
in active and passive smokers: influence of antioxidant supplementation. Journal
of the American College of Nutrition 2004;23:141-147.
12.
Simopoulos, AP. Essential Fatty Acids in Health and Chronic Disease. American
Journal of Clinical Nutrition 1999;70(suppl):560S-569S.
13.
Simopoulos, AP. The Mediterranean diets: What is so special about the diet of
Greece? Journal of Nutrition 2001;131:3065S-3073S.
Readers
have my permission to copy and disseminate all or part of these articles if it
is clearly identified as the work of: Jay S. Cohen, M.D., The Free Underground
MedicationSense E-Newsletter, www.MedicationSense.com.
Click
Here to
share this page with your friends, website visitors, ezine readers, social followers
and other online contacts.
Disclaimer:
Throughout this website, statements are made pertaining to the properties and/or
functions of food and/or nutritional products. These statements have not been
evaluated by the Food and Drug Administration and these materials and products
are not intended to diagnose, treat, cure or prevent any disease.